ANI Pharmaceuticals Inc. (NASDAQ:ANIP) director Thomas Haughey executed a $161,760 stock sale on June 8, 2026, following a pre-arranged trading plan established in March 2026. This transaction follows an earlier acquisition of 4,357 shares via a restricted stock award in May 2026. The sale occurs as the company reports robust first-quarter 2026 financial results, significantly exceeding market expectations for both earnings per share and revenue, reinforcing its position in the specialty pharmaceutical sector.
According to a recent Securities and Exchange Commission filing, Mr. Haughey sold 2,000 shares of ANI Pharmaceuticals common stock at a price of $80.88 per share. The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 9, 2026. This type of plan allows insiders to trade stock in a predetermined manner, helping to avoid potential conflicts of interest or accusations of trading on material non-public information.
Separately, on May 21, 2026, Mr. Haughey acquired 4,357 shares of ANI Pharmaceuticals common stock through a restricted stock award. These shares were granted at a price of $0 and are scheduled to vest in full on May 21, 2027. Following these transactions, Mr. Haughey directly holds 38,878 shares of ANI Pharmaceuticals common stock.
The stock currently trades at $81.85, up over 30% in the past year, reflecting strong investor confidence in the specialty pharmaceutical company’s $1.73 billion market valuation. According to InvestingPro analysis, ANIP appears undervalued based on its Fair Value assessment, placing it among compelling opportunities on the Most Undervalued stocks list. The company maintains a "GREAT" financial health score, with net income expected to grow this year.
In other recent news, ANI Pharmaceuticals Inc. reported strong financial results for the first quarter of 2026, surpassing market expectations. The company achieved an earnings per share (EPS) of $2.05, which was significantly higher than the analysts’ forecast of $1.45. Additionally, ANI Pharmaceuticals’ revenue reached $237.5 million, exceeding the anticipated $213.42 million. These figures indicate a robust performance and demonstrate the company’s ability to outperform projections. While stock price movements are not discussed here, the financial results suggest a positive reception from investors. This development comes amid various market analyses, with some firms potentially revisiting their outlook on ANI Pharmaceuticals. These recent achievements highlight the company’s strong position in the industry.